Open tender · Czechia · Immunosuppressive agents
Imunosupresivum, monoklonální protilátka s obsahovou látkou Teprotumumabum
In EnglishImmunosuppressant, monoclonal antibody with active substance Teprotumumab
Fakultní nemocnice Ostrava in Czechia is inviting bids for “Immunosuppressant, monoclonal antibody with active substance Teprotumumab”. Bids close on 13 October 2026, 10:00 CEST; the estimated value is CZK 105 million. askTender lists every requirement to qualify and checks whether your company meets them.
The tender in brief
Repeated deliveries of the medicine Teprotumumab 500 mg to a hospital in Ostrava, for licensed pharmaceutical suppliers
The buyer is a hospital in Ostrava. It is buying ongoing, repeated deliveries of the medicine Teprotumumabum 500 mg in a single injection vial, ordered through individual purchase orders. The contract is awarded to the lowest total bid price excluding VAT.
Key facts
- Estimated value
- CZK 105 million
- Procedure
- Contract notice
- How bids are judged
- Lowest total bid price excluding VAT
Before you bid, askTender
Everything else is in your askTender account
The requirements to qualify, the eligibility check and the bid documents for this tender are in your askTender account.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences